Gilead Sciences

Gilead Sciences is acquiring Tubulis to expand its oncology pipeline, particularly in antibody-drug conjugates (ADCs). This acquisition strengthens its position in cancer therapies and is expected to accelerate the development of new treatments.

Gilead Sciences is the developer of lenacapavir, a revolutionary HIV prevention injection. The company has already granted six manufacturing licenses to generic drug producers and is open to considering additional partnerships in Sub-Saharan Africa, including South Africa, to expand access to the drug.

Gilead Sciences developed lenacapavir, the long-acting HIV prevention drug being rolled out in African countries. The company has committed to selling the drug at no profit to low and middle-income countries heavily affected by HIV, which is a positive for its corporate social responsibility.

Gilead Sciences is the manufacturer of lenacapavir, the HIV prevention drug being rolled out in Kenya. The company is involved in a partnership with the Kenyan Ministry of Health and The Global Fund to Fight AIDS, Tuberculosis and Malaria to facilitate the drug's distribution.

Gilead Sciences is a prominent company in the CAR T cell market, contributing to its competitiveness through innovation and advancements in treatment approaches.